Bempedoic acid was associated with a 42% relative reduction in first venous thromboembolism event compared with placebo in a post hoc analysis of the CLEAR Outcomes randomized clinical trial.
The signal was directionally consistent for both deep vein thrombosis and pulmonary embolism, with hazard ratios of 0.56 and 0.61, respectively.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
